Scientists have identified a promising target for treatment of a devastating autoimmune disease affecting the brain.
The images showed that nearly all the antibodies bind to a single domain of the receptor, providing a viable target for novel therapeutics.
Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...
No standard treatments for the sometimes deadly disorder have been developed, but that may change due to the newly published ...
Three distinct snapshots obtained with cryo-electron microscopy illustrate the arrangement of two of the four symmetrical subunits that make a functional NMDA receptor. During activation, as the ...
A new study suggests a potential molecular strategy for treating fragile X syndrome, an inherited neurodevelopmental disorder that causes autism spectrum disorder and intellectual disability. This ...
The links between neurons are crucial to the brain, and brain cells can reorganize the way they are linked together in a phenomenon known as neuroplasticity. This process is ongoing during a lifetime, ...
Ben Tarver’s night terrors were the first symptoms of Anti-NMDA Receptor Encephalitis, a rare autoimmune disorder that landed him in the ICU Liam Nougher / SWNS Ben Tarver, 29, began having seizures ...
Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback